Cingulate (CINGW) Non Operating Investment Income (2022)

Cingulate's (CINGW) quarterly Non Operating Investment Income came in at $3249.0 in Q3 2022, up 797.21% quarter-over-quarter from -$466.0 in Q2 2022.

Analysis

Cingulate (CINGW) Non Operating Investment Income (2022) Analysis & Trends

Cingulate (CINGW) has reported Non Operating Investment Income for 1 consecutive years, with $3249.0 the latest figure, recorded in Q3 2022.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non Operating Investment Income (Qtr)
1	Johnson & Johnson	646.03 Bn	625.27 Bn	17.26 Bn	-
2	AbbVie	441.99 Bn	435.42 Bn	12.70 Bn	-
3	Merck	366.30 Bn	359.16 Bn	12.21 Bn	-
4	Novartis Ag	266.55 Bn	258.86 Bn	11.24 Bn	-
5	Pfizer	159.14 Bn	147.45 Bn	10.94 Bn	-
6	Sanofi	52.40 Bn	45.02 Bn	10.79 Bn	-
7	Revolution Medicines	44.13 Bn	44.13 Bn	-	-
8	Incyte	25.53 Bn	20.99 Bn	1.57 Bn	9.81 Mn
9	United Therapeutics	21.51 Bn	18.85 Bn	683.80 Mn	-
10	Cingulate	100,214.03	100,214.03	-	-

Historic Data

Download Data